77-LB: A Retrospective Analysis of the Association between HbA1c and Continuous Glucose Monitor Use for U.S. Patients with Type 2 Diabetes
| Autor: | Tim Bancroft, Gregory J. Norman, Misti L. Paudel, P. Lynch |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
education.field_of_study endocrine system diseases Treatment regimen business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment Population nutritional and metabolic diseases Type 2 diabetes medicine.disease law.invention Regimen Randomized controlled trial law Internal medicine Internal Medicine medicine Retrospective analysis education business Glycemic |
| Zdroj: | Diabetes. 70 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db21-77-lb |
| Popis: | Background: Use of real-time continuous glucose monitoring (rtCGM) reduces HbA1c in individuals with type 2 diabetes (T2D) treated with intensive insulin regimens in randomized clinical trials. However, the effects of CGM use on glycemia in T2D patients in real world settings, particularly those treated with less intensive therapies, has not been well studied. Materials and Methods: This large retrospective, observational analysis utilized data from the Optum Research Database (ORD) to assess the glycemic effects of CGM use (any CGM or real-time CGM [rtCGM]) compared with self-monitoring of blood glucoses (SMBG) within a large T2D population treated with intensive insulin therapy (IIT) and non-intensive therapies (NIT), including basal insulin only, and non-insulin medications. Outcomes were changes from baseline in HbA1c up to 6 months post index date in all patients and by treatment regimen. The percentage of patients who achieved ≥1.0 HbA1c reductions was also assessed. Results: Data from 82,983 eligible patients were assessed (Any CGM, n=1,406; rtCGM, n=148; SMBG, n=81,575). Significant HbA1c reductions were observed with Any CGM (-0.46) and rtCGM (-0.72) vs. SMBG (-0.09), ps < 0.001. HbA1c reductions were significant in CGM vs. SMBG users in the ITT (Any CGM, -0.38%; rtCGM, -0.68%, ps Conclusions: Use of CGM (Any CGM or rtCGM) confers notable benefits in improving glycemic control regardless of therapy regimen. These findings support expanding CGM access to the broader T2D population. Disclosure G. J. Norman: Employee; Self; Dexcom, Inc. M. L. Paudel: None. T. Bancroft: None. P. M. Lynch: Employee; Self; Dexcom, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|